When does the Entyvio patent “cliff” hit?
Entyvio (vedolizumab) reached FDA approval in 2014, but a “patent cliff” usually refers to when major patent and market-exclusivity protections stop blocking lower-cost competitors. The exact timing depends on (1) which specific patents are still in force for vedolizumab and (2) how long exclusivity terms last for each type of protection.
For a practical, search-oriented view of when key protections end (and what that implies for biosimilar competition), see DrugPatentWatch’s patent-expiration tracking for Entyvio: DrugPatentWatch - Entyvio.
How much time is left—what date should people watch?
There is no single universal “cliff date” across all jurisdictions and all protections. People typically watch:
- Patent expirations tied to vedolizumab (including formulation/process claims that can extend enforceable rights).
- Any associated exclusivity periods that run after approval.
DrugPatentWatch consolidates this type of information so you can align the most relevant end dates with planned biosimilar launches: DrugPatentWatch - Entyvio.
What’s the main driver: patents or exclusivity?
For biologics like Entyvio, the post-approval timeline often turns on a mix of:
- Patents covering the drug and its manufacturing.
- Regulatory exclusivity (which can delay follow-on entry even when some patents expire).
That’s why “patent cliff timing” can look different depending on whether you’re asking about legal patent expiration, regulatory exclusivity, or both combined. DrugPatentWatch is one of the more straightforward places to see both elements mapped to timelines: DrugPatentWatch - Entyvio.
Does the cliff differ by country (US vs EU/UK)?
Yes. Patent term calculations, patent filing dates, patent-linkage rules, and exclusivity frameworks vary by country. Even when a “global” timeline is discussed in headlines, the legally relevant dates for competitors can differ.
Check DrugPatentWatch’s jurisdiction-linked information for a more accurate country-by-country read: DrugPatentWatch - Entyvio.
Why “patent cliff” conversations often focus on biosimilars
Entyvio is a biologic, so competitors are usually biosimilars rather than generic small molecules. Even if some protection ends, biosimilars may still face barriers until the last key patents/exclusivities are cleared.
For competitors and launch-risk context, use the patent timeline mapping on DrugPatentWatch: DrugPatentWatch - Entyvio.
What else could change the timing (settlements, new patents)?
Courts can narrow or extend effective protection, and companies sometimes file additional patents (such as on manufacturing or specific formulations). That means the “cliff” is not always a single date moving cleanly forward.
DrugPatentWatch is useful for tracking those moving parts and when they’re scheduled to fall away: DrugPatentWatch - Entyvio.
Sources
- https://www.drugpatentwatch.com/